Is this you? Create Your Porfile

Amy J. Johnson

The Ohio State University Wexner Medical Center

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Amy J. Johnson is active.

Explore More

Publication

Featured researches published by Amy J. Johnson.

Cancer | 2018

Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia: Cancer Stress

Barbara L. Andersen; Neha Godiwala Goyal; David M. Weiss; Travis D. Westbrook; Kami Maddocks; John C. Byrd; Amy J. Johnson

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia, with profound disease‐related cellular, humoral, and innate immune suppression. The objective of this study was to study the correlations between stress and disease‐specific, negative prognostic cellular, cytokine, and chemokine markers in patients with CLL.

Archive | 2014

response to therapy distinct molecular characteristics and does not indicate a suboptimal Prolonged lymphocytosis during ibrutinib therapy is associated with

Danelle F. James; Fong Clow; Gerard Lozanski; Amy J. Johnson; John C. Byrd; Rose Mantel; Jeffrey A. Jones; Joseph M. Flynn; Kami Maddocks; Susan O'Brien; Richard R. Furman; David M. Lucas; Katie Williams; Weiqiang Zhao; Laura Z. Rassenti; Emanuela M. Ghia; Thomas J. Kipps; Jennifer A. Woyach; Kelly A. Smucker; Lisa L. Smith; Arletta Lozanski; Yiming Zhong; Amy S. Ruppert

Archive | 2013

in chronic lymphocytic leukemia Selective inhibitors of nuclear export show that CRM1/XPO1 is a target

Dilara McCauley; Sharon Shacham; Michael Kauffman; John C. Byrd; Amy J. Johnson; David M. Lucas; Dirk Daelemans; Vincent Sandanayaka; Sharon Shechter; Emilia Mahoney; Caroline Berglund; Sneha V. Gupta; Alicia Farmer; Rajeswaran Mani; Rosa Lapalombella; Qingxiang Sun; Katie Williams; Larissa Tangeman; Shruti Jha; Yiming Zhong

Archive | 2013

independent mechanism - Bcl-2 CLL cells and transformed B-cell lymphoma cell line via a caspase- and A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary

Michael R. Grever; Ching Shih Chen; John C. Byrd; Amy J. Johnson; Lisa L. Smith; Jiuxiang Zhu; Nyla A. Heerema; Sara Jefferson; Andrew P. Mone

Archive | 2013

development tool for human chronic lymphocytic leukemia Characterization of the TCL-1 transgenic mouse as a preclinical drug

Carlo M. Croce; Michael R. Grever; John C. Byrd; Amy J. Johnson; David M. Lucas; Natarajan Muthusamy; Lisa L. Smith; Ryan B. Edwards

Archive | 2013

intracellular calcium leukemia cells with impaired oxygen consumption and mobilization of Flavopiridol causes early mitochondrial damage in chronic lymphocytic

Michael R. Grever; Serge Viatchenko-Karpinski; Amy S. Ruppert; John C. Byrd; Periannan Kuppusamy; A. Hussain; David M. Lucas; Amy J. Johnson; Thomas S. Lin; Alan P. Bakaletz

Archive | 2012

protein tyrosine phosphatase PTPROt in leukemia AP-1 elements and TCL1 protein regulate expression of the gene encoding

Xiaokui Mo; David Jarjoura; John C. Byrd; Carlo M. Croce; Samson T. Jacob; Mohamed Kaou; Yiming Zhong; Amy J. Johnson; David M. Lucas; Nyla A. Heerema; John P. Hagan; Tasneem Motiwala; Nicola Zanesi; Jharna Datta; Huban Kutay; Allyn M. Checovich

Archive | 2011

Manuscript no. HAEMATOL/2011/047324 entitled "Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach"

Deborah M. Stephens; Amy S. Ruppert; Kristie A. Blum; Jeffrey A. Jones; Joseph M. Flynn; Amy J. Johnson; Jia Ji; Mitchell Phelps; Michael R. Grever; John C. Byrd

Archive | 2010

survival pathway in human chronic lymphocytic leukemia cells Hu1D10 induces apoptosis concurrent with activation of the AKT

Amy J. Johnson; Sara Jefferson; Thomas S. Lin; John C. Byrd; Andrew P. Mone; Peng Huang; Helene Pelicano; Carolyn Cheney; Jennifer Green; J. Yun Tso

Archive | 2010

chronic lymphocytic leukemia associated with marked clinical efficacy in refractory, genetically high-risk Flavopiridol administered using a pharmacologically derived schedule is

Michael R. Grever; David M. Lucas; Gerard Lozanski; Jose-Ramon Suerez; Avramidis Dimitrios; Brad H. Rovin; Michelle Brooker-McEldowney; Sarah Broering; Larry J. Schaaf; Amy J. Johnson; John C. Byrd; Thomas S. Lin; James T. Dalton; Mitch A. Phelps; Elizabeth A. Fischer; Mollie E. Moran

Explore More